Clinical Trials
10 trialsNCT03276832 2026-03-19
Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma
Mayo Clinic
Phase EARLY_PHASE1 Completed
NCT00142454 2022-10-10
NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)
Ludwig Institute for Cancer Research
Phase 1 Completed
NCT04072900 2020-04-28
A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma
Xiangya Hospital of Central South University
Phase 1 Unknown
NCT00118313 2020-03-27
Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
University of Virginia
Phase 1 Completed
NCT01088737 2019-08-13
Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna
Medical University of Graz
Phase 2/3 Unknown
NCT01191034 2019-03-12
Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 1/2 Terminated
NCT01264731 2016-12-16
MEL53
University of Virginia
Phase 1 Completed
NCT00453050 2015-05-06
Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the Skin
National Cancer Institute (NCI)
Phase 1 Completed
NCT00273910 2012-10-19
Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00651703 2010-11-15
Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients
Cytos Biotechnology AG
Phase 2 Completed